Neuropharmacology and therapeutic potential of cannabinoids

Research output: Contribution to journalLiterature review

63 Citations (Scopus)

Abstract

Mammalian tissues contain at least two types of cannabinoid receptor, CB1, found mainly on neurones and CB2, found mainly in immune cells. Endogenous ligands for these receptors have also been identified. These "endocannabinoids" and their receptors constitute the "endogenous cannabinoid system". Two cannabinoid receptor agonists, Delta(9)-tetrahydrocannabinol and nabilone, are used clinically as anti-emetics or to boost appetite. Additional therapeutic uses of cannabinoids may include the suppression of some multiple sclerosis and spinal injury symptoms, the management of pain, bronchial asthma and glaucoma, and the prevention of neurotoxicity. There are also potential clinical applications for CB1 receptor antagonists, in the management of acute schizophrenia and cognitive/memory dysfunctions and as appetite suppressants. Future research is likely to be directed at characterizing the endogenous cannabinoid system more completely, at obtaining more conclusive clinical data about cannabinoids with regard to both beneficial and adverse effects, at developing improved cannabinoid formulations and modes of administration for use in the clinic and at devising clinical strategies for separating out the sought-after effects of CB1 receptor agonists from their psychotropic and other unwanted effects.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalAddiction Biology
Volume5
Publication statusPublished - 2000

Keywords

  • RECEPTOR-MEDIATED INHIBITION
  • RAT HIPPOCAMPAL-NEURONS
  • CLOSED-HEAD INJURY
  • CB1 RECEPTOR
  • SR 141716A
  • MOLECULAR CHARACTERIZATION
  • PRECIPITATED WITHDRAWAL
  • INDUCED ANTINOCICEPTION
  • ACETYLCHOLINE-RELEASE
  • SELECTIVE-INHIBITION

Cite this

Neuropharmacology and therapeutic potential of cannabinoids. / Pertwee, R G .

In: Addiction Biology, Vol. 5, 2000, p. 37-46.

Research output: Contribution to journalLiterature review

@article{d534618c45834a8f8a854e6268260fc9,
title = "Neuropharmacology and therapeutic potential of cannabinoids",
abstract = "Mammalian tissues contain at least two types of cannabinoid receptor, CB1, found mainly on neurones and CB2, found mainly in immune cells. Endogenous ligands for these receptors have also been identified. These {"}endocannabinoids{"} and their receptors constitute the {"}endogenous cannabinoid system{"}. Two cannabinoid receptor agonists, Delta(9)-tetrahydrocannabinol and nabilone, are used clinically as anti-emetics or to boost appetite. Additional therapeutic uses of cannabinoids may include the suppression of some multiple sclerosis and spinal injury symptoms, the management of pain, bronchial asthma and glaucoma, and the prevention of neurotoxicity. There are also potential clinical applications for CB1 receptor antagonists, in the management of acute schizophrenia and cognitive/memory dysfunctions and as appetite suppressants. Future research is likely to be directed at characterizing the endogenous cannabinoid system more completely, at obtaining more conclusive clinical data about cannabinoids with regard to both beneficial and adverse effects, at developing improved cannabinoid formulations and modes of administration for use in the clinic and at devising clinical strategies for separating out the sought-after effects of CB1 receptor agonists from their psychotropic and other unwanted effects.",
keywords = "RECEPTOR-MEDIATED INHIBITION, RAT HIPPOCAMPAL-NEURONS, CLOSED-HEAD INJURY, CB1 RECEPTOR, SR 141716A, MOLECULAR CHARACTERIZATION, PRECIPITATED WITHDRAWAL, INDUCED ANTINOCICEPTION, ACETYLCHOLINE-RELEASE, SELECTIVE-INHIBITION",
author = "Pertwee, {R G}",
year = "2000",
language = "English",
volume = "5",
pages = "37--46",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Neuropharmacology and therapeutic potential of cannabinoids

AU - Pertwee, R G

PY - 2000

Y1 - 2000

N2 - Mammalian tissues contain at least two types of cannabinoid receptor, CB1, found mainly on neurones and CB2, found mainly in immune cells. Endogenous ligands for these receptors have also been identified. These "endocannabinoids" and their receptors constitute the "endogenous cannabinoid system". Two cannabinoid receptor agonists, Delta(9)-tetrahydrocannabinol and nabilone, are used clinically as anti-emetics or to boost appetite. Additional therapeutic uses of cannabinoids may include the suppression of some multiple sclerosis and spinal injury symptoms, the management of pain, bronchial asthma and glaucoma, and the prevention of neurotoxicity. There are also potential clinical applications for CB1 receptor antagonists, in the management of acute schizophrenia and cognitive/memory dysfunctions and as appetite suppressants. Future research is likely to be directed at characterizing the endogenous cannabinoid system more completely, at obtaining more conclusive clinical data about cannabinoids with regard to both beneficial and adverse effects, at developing improved cannabinoid formulations and modes of administration for use in the clinic and at devising clinical strategies for separating out the sought-after effects of CB1 receptor agonists from their psychotropic and other unwanted effects.

AB - Mammalian tissues contain at least two types of cannabinoid receptor, CB1, found mainly on neurones and CB2, found mainly in immune cells. Endogenous ligands for these receptors have also been identified. These "endocannabinoids" and their receptors constitute the "endogenous cannabinoid system". Two cannabinoid receptor agonists, Delta(9)-tetrahydrocannabinol and nabilone, are used clinically as anti-emetics or to boost appetite. Additional therapeutic uses of cannabinoids may include the suppression of some multiple sclerosis and spinal injury symptoms, the management of pain, bronchial asthma and glaucoma, and the prevention of neurotoxicity. There are also potential clinical applications for CB1 receptor antagonists, in the management of acute schizophrenia and cognitive/memory dysfunctions and as appetite suppressants. Future research is likely to be directed at characterizing the endogenous cannabinoid system more completely, at obtaining more conclusive clinical data about cannabinoids with regard to both beneficial and adverse effects, at developing improved cannabinoid formulations and modes of administration for use in the clinic and at devising clinical strategies for separating out the sought-after effects of CB1 receptor agonists from their psychotropic and other unwanted effects.

KW - RECEPTOR-MEDIATED INHIBITION

KW - RAT HIPPOCAMPAL-NEURONS

KW - CLOSED-HEAD INJURY

KW - CB1 RECEPTOR

KW - SR 141716A

KW - MOLECULAR CHARACTERIZATION

KW - PRECIPITATED WITHDRAWAL

KW - INDUCED ANTINOCICEPTION

KW - ACETYLCHOLINE-RELEASE

KW - SELECTIVE-INHIBITION

M3 - Literature review

VL - 5

SP - 37

EP - 46

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

ER -